168 related articles for article (PubMed ID: 10761869)
1. New agents for Type 2 diabetes.
Nattrass M; Bailey CJ
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Jul; 13(2):309-29. PubMed ID: 10761869
[TBL] [Abstract][Full Text] [Related]
2. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
3. Insulin resistance and its treatment by thiazolidinediones.
Lebovitz HE; Banerji MA
Recent Prog Horm Res; 2001; 56():265-94. PubMed ID: 11237217
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone and related compounds: therapeutic potential beyond diabetes.
Fujiwara T; Horikoshi H
Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
[TBL] [Abstract][Full Text] [Related]
5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
6. [Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Brogard JM; Neyrolles N; Andres E; Blicklé JF
Rev Med Interne; 1999 Aug; 20 Suppl 3():371s-378s. PubMed ID: 10480188
[TBL] [Abstract][Full Text] [Related]
7. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Ohmura E; Hosaka D; Imai Y; Kawazu S
Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
[No Abstract] [Full Text] [Related]
8. Repaglinide in combination therapy.
Moses R
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
[TBL] [Abstract][Full Text] [Related]
9. The use of insulin secretagogues in the treatment of type 2 diabetes.
Luna B; Hughes AT; Feinglos MN
Prim Care; 1999 Dec; 26(4):895-915. PubMed ID: 10523467
[TBL] [Abstract][Full Text] [Related]
10. Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group.
Buysschaert M; Bobbioni E; Starkie M; Frith L
Diabet Med; 1999 Feb; 16(2):147-53. PubMed ID: 10229309
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic management of diabetes mellitus.
Mozersky RP
J Am Osteopath Assoc; 1999 Dec; 99(12 Suppl):S15-9. PubMed ID: 10659525
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic therapy for type 2 diabetes mellitus.
DeFronzo RA
Ann Intern Med; 1999 Aug; 131(4):281-303. PubMed ID: 10454950
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
14. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
Scheen AJ; Lefèbvre PJ
Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527
[TBL] [Abstract][Full Text] [Related]
15. New drugs for diabetes.
Tack CJ; Smits P
Neth J Med; 1999 Nov; 55(5):209-11. PubMed ID: 10593129
[No Abstract] [Full Text] [Related]
16. Pharmacotherapy of type 2 diabetes mellitus.
Rendell MS; Kirchain WR
Ann Pharmacother; 2000; 34(7-8):878-95. PubMed ID: 10928401
[TBL] [Abstract][Full Text] [Related]
17. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.
Shimaya A; Kurosaki E; Nakano R; Hirayama R; Shibasaki M; Shikama H
Metabolism; 2000 Mar; 49(3):411-7. PubMed ID: 10726922
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinediones: a new class of antidiabetic drugs.
Day C
Diabet Med; 1999 Mar; 16(3):179-92. PubMed ID: 10227562
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones--the new insulin enhancers.
Jha RJ
Clin Exp Hypertens; 1999; 21(1-2):157-66. PubMed ID: 10052651
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Krentz AJ; Bailey CJ; Melander A
BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
[No Abstract] [Full Text] [Related]
[Next] [New Search]